Top Markets
Coin of the day
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5
Classifica tra le azioni #15973
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Prezzo delle azioni
$15.42
Capitalizzazione di mercato
$320.83M
Variazione (1 giorno)
-1.52%
Variazione (1 anno)
40.67%
Paese
IT
Scambia Newron Pharmaceuticals S.p.A. (NP5)

Categoria

Rapporto P/B per Newron Pharmaceuticals S.p.A. (NP5)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Newron Pharmaceuticals S.p.A., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Newron Pharmaceuticals S.p.A. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH